advertisement

China rituximab market 2018

33 %
67 %
advertisement
Information about China rituximab market 2018
Business & Mgmt

Published on February 28, 2014

Author: systemk990

Source: slideshare.net

Description

Rituximab (trade names "MabThera" by Roche, "Rituxan" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of Bcell lymphoma. As people understand more about Bcell and its action mechanism, it is acknowledged that besides Bcell malignancies rituximab can also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from 2010 to 2012 respectively.
advertisement

Investigation Report on China Rituximab Market, 2009-2018 by China Research and Intelligence Explore all reports for “Life Sciences” market @ http://www.chinamarketresearchreports.com/cat/li fe-sciences.html. © ChinaMarketResearchReports.com ; sales@chinamarketresearchreports.com ; +1 888 391 5441

Investigation Report on China Rituximab Market, 2009-2018 Rituximab (trade names "MabThera" by Roche, "Rituxan" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of Bcell lymphoma. As people understand more about Bcell and its action mechanism, it is acknowledged that besides Bcell malignancies rituximab can also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from 2010 to 2012 respectively. Statistics shows that incidence of nonHodgkin lymphomas in China has increased steeply from 20/1,000,000 at the end of the 20th century to 70/1,000,000 at present. Autoimmune diseases can harm central nervous system and organs such as lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be lifethreatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such high incidence should be taken seriously by the public. Inquire for a discount on this report @ http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=114 © ChinaMarketResearchReports.com ; 727 . sales@chinamarketresearchreports.com ; +1 888 391 5441

Investigation Report on China Rituximab Market, 2009-2018 By the first quarter of 2014, there were no products from local manufacturers on the market, which was completely occupied by Roche. Early 2014, monoclonal antibody drug "recombinant humanmouse chimeric antiCD20 monoclonal antibody injection" produced by Hisun was approved clinical. It is a generic drug of Roche's monoclonal antibody "Rituximab". Five manufacturers in China have reported clinical use of rituximab generic drug. It is estimated that more generic drugs will go on the market in the next few years. According to CRI's investigation on certain sample hospitals in China, the CAGR of sales value of rituximab surpassed 35% from 2005 to 2012. Rituximab is expected to have huge room to grow in future Chinese market. Through this report, the readers can acquire the following information: Market Share of Major Rituximab Manufacturers in China Sample Hospitals Sales Price of Rituximab in China Hospital Market Market Share of Rituximab by Dosage Form in China Hospital Market Incidence of Autoimmune Diseases in China Manufacturing Schedule of Rituximab Generic Drug Prospect of China Rituximab Market Complete report available @ http://www.chinamarketresearchreports.com/114727.html . © ChinaMarketResearchReports.com ; sales@chinamarketresearchreports.com ; +1 888 391 5441

Add a comment

Related presentations

Canvas Prints at Affordable Prices make you smile.Visit http://www.shopcanvasprint...

30 Días en Bici en Gijón organiza un recorrido por los comercios históricos de la ...

Con el fin de conocer mejor el rol que juega internet en el proceso de compra en E...

With three established projects across the country and seven more in the pipeline,...

Retailing is not a rocket science, neither it's walk-in-the-park. In this presenta...

What is research??

What is research??

April 2, 2014

Explanatory definitions of research in depth...

Related pages

Investigation Report on China Rituximab Market, 2009-2018

Table of Contents for Investigation Report on China Rituximab Market, 2009-2018 by China Research and Intelligence Available at ChinaMarketResearchReports.com.
Read more

Investigation Report on China Rituximab Market, 2009-2018 ...

[40 Pages Report] Check for Discount on Investigation Report on China Rituximab Market, 2009-2018 report by China Research and Intelligence. Rituximab ...
Read more

Investigation Report on China Rituximab Market, 2009-2018 ...

Investigation Report on China Rituximab Market, 2009-2018 published in Feb 2014 Available for US $ 1800 at ChinaMarketResearchReports.com - Buy Now or ...
Read more

China Rituximab Market 2018 - PdfSR.com

Investigation Report on China Rituximab Market, 2009-2018 By the first quarter of 2014, there were no products from local manufacturers on the market ...
Read more

Investigation Report on China Rituximab Market, 2009-2018

Rituximab (trade names 'MabThera' by Roche, 'Rituxan' by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor.
Read more

Investigation Report on China Rituximab Market, 2009-2018 ...

Investigation Report on China Rituximab Market, 2009-2018 is a market research report available at US $1800 for a Single User PDF License from RnR Market ...
Read more

China Rituximab Industry 2009-2018 | China - UFO

China Telmisartan Industry 2009-2018; China Insulin Glargine Market 2009-2018; China Bevacizumab Industry 2009-2018; China Montelukast Industry ...
Read more